Get notified when RIGL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRigel completes $70M acquisition of exclusive global rights to VEPPANU cancer drug
Filed June 17, 2026 · Period ending June 11, 2026 · ~1 min read
Key Changes
-
high
Rigel paid $70M upfront to Arvinas and Pfizer for exclusive worldwide rights to develop, manufacture, and commercialize VEPPANU (vepdegestrant) after early HSR antitrust clearance.
Item 2.01 verify on EDGAR → -
high
The license grants Rigel sole global control of the drug candidate across its full commercial lifecycle, positioning the company as the only entity developing vepdegestrant worldwide.
Item 2.01 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FDS 10-Q) is open in full — no account needed.
Partner
Trade RIGL commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jul 7, 2026 · How we verify